Summary

Melanoma Therapeutics Market – Scope of Report
TMR’s report on the global melanoma therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global melanoma therapeutics market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global melanoma therapeutics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the melanoma therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global melanoma therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global melanoma therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global melanoma therapeutics market.

The report delves into the competitive landscape of the global melanoma therapeutics market. Key players operating in the global melanoma therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global melanoma therapeutics market profiled in this report.

Key Questions Answered in Global melanoma therapeutics Market Report
• What is the sales/revenue generated by melanoma therapeutics across all regions during the forecast period?
• What are the opportunities in the global melanoma therapeutics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Melanoma Therapeutics Market – Research Objectives and Research Approach
The comprehensive report on the global melanoma therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global melanoma therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global melanoma therapeutics market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Melanoma Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Melanoma Therapeutics Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Melanoma Therapeutics Market Analysis and Forecast, by Therapy Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Therapy Type, 2020-2034
6.3.1. Chemotherapy
6.3.2. Immunotherapy
6.3.3. Targeted Therapy
6.3.4. Radiation Therapy
6.3.5. Surgery
6.4. Market Attractiveness Analysis, by Therapy Type
7. Global Melanoma Therapeutics Market Analysis and Forecast, by Disease Indication
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Disease Indication, 2020-2034
7.3.1. Superficial Spreading Melanoma
7.3.2. Nodular Melanoma
7.3.3. Lentigo Maligna Melanoma
7.3.4. Acral Lentiginous Melanoma
7.3.5. Desmoplastic Melanoma
7.4. Market Attractiveness Analysis, by Disease Indication
8. Global Melanoma Therapeutics Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2020-2034
8.3.1. Hospitals & Specialty Clinics
8.3.2. Homecare Settings
8.3.3. Others (Academic Institutes, etc.)
8.4. Market Attractiveness Analysis, by End-user
9. Global Melanoma Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Melanoma Therapeutics Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Therapy Type, 2020-2034
10.3.1. Chemotherapy
10.3.2. Immunotherapy
10.3.3. Targeted Therapy
10.3.4. Radiation Therapy
10.3.5. Surgery
10.4. Market Value Forecast, by Disease Indication, 2020-2034
10.4.1. Superficial Spreading Melanoma
10.4.2. Nodular Melanoma
10.4.3. Lentigo Maligna Melanoma
10.4.4. Acral Lentiginous Melanoma
10.4.5. Desmoplastic Melanoma
10.5. Market Value Forecast, by End-user, 2020-2034
10.5.1. Hospitals & Specialty Clinics
10.5.2. Homecare Settings
10.5.3. Others (Academic Institutes, etc.)
10.6. Market Value Forecast, by Country, 2020-2034
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Therapy Type
10.7.2. By Disease Indication
10.7.3. By End-user
10.7.4. By Country
11. Europe Melanoma Therapeutics Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Therapy Type, 2020-2034
11.3.1. Chemotherapy
11.3.2. Immunotherapy
11.3.3. Targeted Therapy
11.3.4. Radiation Therapy
11.3.5. Surgery
11.4. Market Value Forecast, by Disease Indication, 2020-2034
11.4.1. Superficial Spreading Melanoma
11.4.2. Nodular Melanoma
11.4.3. Lentigo Maligna Melanoma
11.4.4. Acral Lentiginous Melanoma
11.4.5. Desmoplastic Melanoma
11.5. Market Value Forecast, by End-user, 2020-2034
11.5.1. Hospitals & Specialty Clinics
11.5.2. Homecare Settings
11.5.3. Others (Academic Institutes, etc.)
11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Therapy Type
11.7.2. By Disease Indication
11.7.3. By End-user
11.7.4. By Country/Sub-region
12. Asia Pacific Melanoma Therapeutics Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Therapy Type, 2020-2034
12.3.1. Chemotherapy
12.3.2. Immunotherapy
12.3.3. Targeted Therapy
12.3.4. Radiation Therapy
12.3.5. Surgery
12.4. Market Value Forecast, by Disease Indication, 2020-2034
12.4.1. Superficial Spreading Melanoma
12.4.2. Nodular Melanoma
12.4.3. Lentigo Maligna Melanoma
12.4.4. Acral Lentiginous Melanoma
12.4.5. Desmoplastic Melanoma
12.5. Market Value Forecast, by End-user, 2020-2034
12.5.1. Hospitals & Specialty Clinics
12.5.2. Homecare Settings
12.5.3. Others (Academic Institutes, etc.)
12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Therapy Type
12.7.2. By Disease Indication
12.7.3. By End-user
12.7.4. By Country/Sub-region
13. Latin America Melanoma Therapeutics Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Therapy Type, 2020-2034
13.3.1. Chemotherapy
13.3.2. Immunotherapy
13.3.3. Targeted Therapy
13.3.4. Radiation Therapy
13.3.5. Surgery
13.4. Market Value Forecast, by Disease Indication, 2020-2034
13.4.1. Superficial Spreading Melanoma
13.4.2. Nodular Melanoma
13.4.3. Lentigo Maligna Melanoma
13.4.4. Acral Lentiginous Melanoma
13.4.5. Desmoplastic Melanoma
13.5. Market Value Forecast, by End-user, 2020-2034
13.5.1. Hospitals & Specialty Clinics
13.5.2. Homecare Settings
13.5.3. Others (Academic Institutes, etc.)
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Therapy Type
13.7.2. By Disease Indication
13.7.3. By End-user
13.7.4. By Country/Sub-region
14. Middle East & Africa Melanoma Therapeutics Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Therapy Type, 2020-2034
14.3.1. Chemotherapy
14.3.2. Immunotherapy
14.3.3. Targeted Therapy
14.3.4. Radiation Therapy
14.3.5. Surgery
14.4. Market Value Forecast, by Disease Indication, 2020-2034
14.4.1. Superficial Spreading Melanoma
14.4.2. Nodular Melanoma
14.4.3. Lentigo Maligna Melanoma
14.4.4. Acral Lentiginous Melanoma
14.4.5. Desmoplastic Melanoma
14.5. Market Value Forecast, by End-user, 2020-2034
14.5.1. Hospitals & Specialty Clinics
14.5.2. Homecare Settings
14.5.3. Others (Academic Institutes, etc.)
14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Therapy Type
14.7.2. By Disease Indication
14.7.3. By End-user
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. Bristol-Myers Squibb Company
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. AstraZeneca plc
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Novartis AG
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Merck & Co., Inc.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Amgen Inc.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. F. Hoffmann-La Roche AG
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Abbott Laboratories
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview